Development of new cancer therapeutic agents targeting mitosis

Bibliography

• HAIT WN, RUBIN E, GOODIN S: Tubulin-targeting agents. Cancer Chemother. Biol. Res. Modif (2005) 22:35-59.
   Google Scholar
• KUPPENS IE: Current state of the art of new tubulin inhibitors in the clinic. Curr. Clin. Pharmacol. (2006) 1:57-70.
   PubMedGoogle Scholar
• PELLEGRINI F, BUDMAN DR: Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. (2005) 23:264-273.
   PubMed Web of Science ®Google Scholar
• GOETZ AD, DENIS LJ, ROWINSKY EK et al.: Phase I and pharmacokinetic study of RPR116258A, a novel taxane derivative, administered intravenously over 1 hour every 3 weeks. Proc. Am. Soc. Clin. Oncol. (2001) 20:419 (Abstract).
   Web of Science ®Google Scholar
• PIVOT X, KORALEWSKI P, HIDALGO JL et al.: Multicenter Phase II study of XRP6258 in taxane-resistant metastatic breast cancer (MBC) patients (pts). Breast Cancer Res. Treat. (2005) 94(Suppl. 1):S68.
   Google Scholar
• ROSE WC, FAIRCHILD C, LEE FY: Preclinical antitumor activity of two novel taxanes. Cancer Chemother. Pharmacol. (2001) 47:97-105.
   PubMed Web of Science ®Google Scholar
• GARRETT CR, FISHMAN MN, RAGO RR et al.: Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. Clin. Cancer Res. (2005) 11:3335-3341.
   PubMed Web of Science ®Google Scholar
• SUN W, STEVENSON JP, GALLAGHER ML et al.: Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. Clin. Cancer Res. (2003) 9:5221-5227.
   PubMed Web of Science ®Google Scholar
• ADVANI R, FISHER GA, LUM BL et al.: Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin. Cancer Res. (2003) 9:5187-5194.
   PubMed Web of Science ®Google Scholar
• EMERSON DL, BELL C, JONES ME, SCHIEMANN B, TAPOLSKY G: Oral bioavailabity and antitumor activity of TPI 287 a new taxane analog with greater activity than paclitaxel against tumor cells with demonstrated mutant tubulin. Proc. Am. Assoc. Cancer Res. (2006) 47:493 (Abstract).
   Google Scholar
• LARKIN​‌ JM, KAYE​ SB: Epothilones in the treatment of cancer. Expert Opin. Investig. Drugs (2006) 15(6):691-702.
   PubMed Web of Science ®Google Scholar
• RUBIN EH, ROTHERMEL J, TESFAYE F et al.: Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J. Clin. Oncol. (2005) 23:9120-9129.
   PubMed Web of Science ®Google Scholar
• RICART AD, CHU QS, DE BONO JS et al.: Phase I study of BMS-247550, an epothilone B analog, administered weekly for 3 weeks followed by a one-week break in patients (pts) with advanced malignancies Proc. Am. Assoc. Cancer Res. (2006) 47:2915 (Abstract).
   Google Scholar
• CHOU T, ZHANG X, DONG H et al.: Therapeutic evaluation of the second generation epothilone, dehydelone, as a microtubule stabilization antitumor agent in xenograft models. Proc. Am. Assoc. Cancer Res. (2006) 47:492 (Abstract).
   Google Scholar
• STOPECK A, THOMAS E, JONES S et al.: Phase I trial of a novel epothilone, KOS-1584, using a weekly dosing schedule. J. Clin. Oncol. (2006) 24:2041.
   Web of Science ®Google Scholar
• CHOU T, ZHANG X, HARRIS CR et al.: Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc. Natl. Acad. Sci. USA (1998) 95:15798-15802.
   PubMed Web of Science ®Google Scholar
• LEE FY, BORZILLERI R, FAIRCHILD CR et al.: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. (2001) 7:1429-1437.
   PubMed Web of Science ®Google Scholar
• HSIN KW, BOYER M, DUCREUX M et al.: Efficacy of patupilone in advanced local or metastatic gastric cancer: a Phase IIa trial. J. Clin. Oncol. (2006) 24:4069.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD RP, McCOY S, RIVKIN SE et al.: A Phase II trial of epothilone B analog BMS-247550 (NSC 710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest. New Drugs (2006) 24(6):515-520.
   PubMed Web of Science ®Google Scholar
• HUSSAIN M, TANGEN CM, LARA PN Jr et al.: Ixabepilone (epothilone B analog BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J. Clin. Oncol. (2005) 23:8724-8729.
   PubMed Web of Science ®Google Scholar
• DENDULURI N, LEE JJ, WALSHE JM et al.: Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes. J. Clin. Oncol. (2006) 24:651.
   Google Scholar
• LOW JA, WEDAM SB, LEE JJ et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol. (2005) 23:2726-2734.
   PubMed Web of Science ®Google Scholar
• BUZDAR A, SILVERMAN P, KAUFMAN PA et al.: A Phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results. Breast Cancer Res. Treat. (2005) 94:S69.
   Google Scholar
• BAI RL, PAULL KD, HERALD CL, MALSPEIS L, PETTIT GR, HAMEL E: Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. (1991) 266:15882-15889.
   PubMed Web of Science ®Google Scholar
• BLUM J, FORERO L, HEISKALA MK et al.: E7389, a novel anti-tubulin, in patients with refractory breast cancer. J. Clin. Oncol. (2006) 24:653.
   Google Scholar
• BENNOUNA J, CAMPONE M, DELORD JP, PINEL MC: Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin. Investig. Drugs (2005) 14:1259-1267.
   PubMed Web of Science ®Google Scholar
• HILL BT: Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical cevelopment and prospects for future mitotic blockers. Curr. Pharm. Des. (2001) 7:1199-1212.
   PubMed Web of Science ®Google Scholar
• FUMOLEAU P, CAMPONE M, VOROBIOF D et al.: Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure. J. Clin. Oncol. (200422:542
   Google Scholar
• GOLDSTEIN D, ACKLAND SP, BELL DR et al.: Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Invest. New Drugs (2006) 24(5):429-434.
   PubMed Web of Science ®Google Scholar
• YOSHIMATSU K, YAMAGUCHI A, YOSHINO H, KOYANANGI N, KITOH K: Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. (1997) 57:3208-3213.
   PubMed Web of Science ®Google Scholar
• HANDE KR, HAGEY A, BERLIN J et al.: The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a Phase I study. Clin. Cancer Res. (2006) 12:2834-2840.
   PubMed Web of Science ®Google Scholar
• FOX E, ADAMSON PC, HAGEY A et al.: Phase I trial of oral ABT-751 in pediatric patients: preliminary evidence of activity in neuroblastoma (NBL). J. Clin. Oncol. (2005) 23: 8527.
   Google Scholar
• MAUER AM, SZETO L, BELT RJ et al.: Preliminary results of a Phase II study of ABT-751 in patients (pts) with taxane-refractory non-small cell lung carcinoma (NSCLC) J. Clin. Oncol. (2005) 23:7137.
   Google Scholar
• BENSON AB, KINDLER HL, JODRELL D et al.: Phase II study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC). J. Clin. Oncol. (2005) 23:3537.
   Web of Science ®Google Scholar
• WASHINGTON DK, STORNIOLO AV, SALEH M aet al.: Phase II results of ABT-751 in subjects with taxane-refractory breast cancer: interim analysis. J. Clin. Oncol. (2005) 23:724.
   Google Scholar
• HAGEY AE, FIGLIN RA, MOLDAWER N et al.: Preliminary Phase II results of ABT-751 in subjects with advanced renal cell carcinoma (RCC). J. Clin. Oncol. (2005) 23:4603.
   Google Scholar
• D’AMATO RJ, LIN CM, FLYNN E, FOLKMAN J, HAMEL E: 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA (1994) 91:3964-3968.
   PubMed Web of Science ®Google Scholar
• LA VALLEE TM, ZHAN XH, JOHNSON MS et al.: Pribluda versus 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. (2003) 63:468-475.
   PubMed Web of Science ®Google Scholar
• BAICHWAL V, KASIBHATLA S, ROTH B et al.: MPC-6827: A small molecule inhibitor of microtubule formation that is not a substrate for multi-drug resistance pumps. Proc. Am. Assoc. Cancer Res. (2005) 46:3416 (Abstract).
   Google Scholar
• TSENG B, KASIBHATLA S, PERVIN A et al.: MX90745, a new family of apoptosis inducing molecules with potent in vivo anti-cancer activities. Proc. Am. Assoc. Cancer Res. (2004) 45:5361 (Abstract).
   Google Scholar
• PLEIMAN CM, VON HOFF D, DEMIE L et al.: Antitumor activity of MPC-6827 in human breast, colon, pancreatic, ovarian and mouse melanoma tumor xenografts in athymic nude mice. Proc. Am. Assoc. Cancer Res. (2004) 45:LB252 (Abstract).
   Google Scholar
• LESLIE EM, DEELEY RG, COLE SP: Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. (2005) 204:216-237.
   PubMed Web of Science ®Google Scholar
• HAIMEUR A, CONSEIL G, DEELEY RG, COLE SP: The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. (2004) 5:21-53.
   PubMed Web of Science ®Google Scholar
• JESSING K, MAUCK K, BRADFORD C et al.: MPC-6827, a small molecule inhibitor of microtubule formation with high brain penetration: absorption, distribution, metabolism, excretion, and clinical considerations. Proc. Am. Assoc. Cancer Res. (2005) 46:3413 (Abstract).
   Google Scholar
• BAUER B, HARTZ AM, FRICKER G, MILLER DS: Modulation of P-glycoprotein transport function at the blood–brain barrier. Exp. Biol. Med. (Maywood) (2005) 230:118-127.
   PubMed Web of Science ®Google Scholar
• KUSUHARA H, SUGIYAMA Y: Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx (2005) 2:73-85.
   PubMedGoogle Scholar
• LÖSCHER W, POTSCHKA H: Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx (2005) 2:86-98.
   PubMedGoogle Scholar
• GLANTZ MJ, CHOY H, KEARNS CM et al.: Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J. Natl. Cancer Inst. (1995) 87:1077-1081.
   Google Scholar
• RICE A, LIU Y, MICHAELIS ML et al.: Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood–brain barrier in vitro and in situ. J. Med. Chem. (2005) 48(3):832-838.
   PubMed Web of Science ®Google Scholar
• KEMPER EM, VAN ZANDBERGEN AE, CLEYPOOL C et al.: Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin. Cancer Res. (2003) 9:2849-2855.
   PubMed Web of Science ®Google Scholar
• VAN ASPEREN J, VAN TELLINGEN O, SCHINKEL AH, BEIJNEN JH: Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein. J. Pharmacol. Exp. Ther. (1999) 289:329-333.
   PubMed Web of Science ®Google Scholar
• RENES J, DE VRIES EGE, JANSEN PLM, MÜLLER M: The (patho)physiological functions of the MRP family. Drug Resistance Updates (2000) 3:287-300.
   Google Scholar
• DOYLE LA, ROSS DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene (2003) 22:7340-7358.
   PubMed Web of Science ®Google Scholar
• LEONARD GD, FOJO T, BATES SE: The role of ABC transporters in clinical practice. Oncologist (2003) 8:411-424.
   PubMed Web of Science ®Google Scholar
• DOOLITTLE ND, ANDERSON CP, BLEYER WA et al.: Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro-oncol. (2001) 3:46-56.
   PubMedGoogle Scholar
• SIEMANN DW, BIBBY MC, DARK GG et al.: Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. (2005) 15:416-420.
   Google Scholar
• McGOWN AT, FOX BW: Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anti-Cancer Drug Des. (1989) 3:249-254.
   PubMedGoogle Scholar
• RICART AD, COONEY M, SARANTOPOULOS J et al.: A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors. J. Clin. Oncol. (2006) 24:3096.
   Google Scholar
• NICHOLSON B, LLOYD GK, MILLER BR et al.: NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anti-Cancer Drugs (2006) 17:25-31.
   PubMed Web of Science ®Google Scholar
• TOZER GM, KANTHOU C, BAGULEY BC: Disrupting tumour blood vessels. Nat. Rev. Cancer (2005) 5:423-435.
   PubMed Web of Science ®Google Scholar
• SIEMANN DW, CHAPLIN DJ, HORSMAN MR: Vascular-targeting therapies for treatment of malignant disease. Cancer (2004) 100:2491-2499.
   PubMed Web of Science ®Google Scholar
• COONEY MM, SAVVIDES P, AGARWALA S et al.: Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J. Clin. Oncol. (2006) 24:5580.
   Google Scholar
• RICART AD, COONEY M, SARANTOPOULOS J et al.: A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors. J. Clin. Oncol. (2006) 24:3096.
   Google Scholar
• HIROKAWA N: Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science (1998) 279(5350):519-526.
   PubMed Web of Science ®Google Scholar
• ENDOW SA: Kinesin motors as molecular machines. BioEssays (2003) 25(12):1212-1219.
   PubMed Web of Science ®Google Scholar
• GADDE S, HEALD R: Mechanisms and molecules of the mitotic spindle. Curr. Biol. (2004) 14(18):R797-R805.
   PubMed Web of Science ®Google Scholar
• YILDIZ A, SELVIN PR: Kinesin: walking, crawling or sliding along? Trends Cell Biol. (2005) 15(2):112-120.
   PubMed Web of Science ®Google Scholar
• NEEF R, KLEIN UR, KOPAJTICH R, BARR FA: Cooperation between mitotic kinesins controls the late stages of cytokinesis. Curr. Biol. (2006) 16(3):301-307.
   PubMed Web of Science ®Google Scholar
• ANDREWS PD: Aurora kinases: shining lights on the therapeutic horizon? Oncogene (2005) 24(32):5005-5015.
   PubMed Web of Science ®Google Scholar
• CARMENA M, EARNSHAW WC: The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. (2003) 4(11):842-854.
   PubMed Web of Science ®Google Scholar
• WARNER SL, BEARSS DJ, HAN H, VON HOFF DD: Targeting Aurora-2 kinase in cancer. Mol. Cancer Ther. (2003) 2(6):589-595.
   PubMed Web of Science ®Google Scholar
• VAN VUGT MA, MEDEMA RH: Getting in and out of mitosis with Polo-like kinase-1. Oncogene (2005) 24(17):2844-2859.
   PubMed Web of Science ®Google Scholar
• LOWERY DM, LIM D, YAFFE MB: Structure and function of Polo-like kinases. Oncogene (2005) 24(2):248-259.
   PubMed Web of Science ®Google Scholar
• ENDOW SA: Microtubule motors in spindle and chromosome motility. Eur. J. Biochem. (1999) 262(1):12-18.
   PubMedGoogle Scholar
• BLANGY A, LANE HA, D’HERIN P et al.: Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell (1995) 83(7):1159-1169.
   PubMed Web of Science ®Google Scholar
• MIKI H, OKADA Y, HIROKAWA N: Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol. (2005) 15(9):467-476.
   PubMed Web of Science ®Google Scholar
• MIKI H, SETOU M, KANESHIRO K, HIROKAWA N: All kinesin superfamily protein, KIF, genes in mouse and human. Proc. Natl. Acad. Sci. USA (2001) 98(13):7004-7011.
   Google Scholar
• MAYER TU, KAPOOR TM, HAGGARTY SJ et al.: Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science (1999) 286(5441):971-974.
   PubMed Web of Science ®Google Scholar
• SAKOWICZ R, FINER JT, BERAUD C et al.: Antitumor activity of a kinesin inhibitor. Cancer Res. (2004) 64(9):3276-3280.
   PubMed Web of Science ®Google Scholar
• COX CD, BRESLIN MJ, MARIANO BJ et al.: Kinesin spindle protein (KSP) inhibitors. Part 1: the discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett. (2005) 15(8):2041-2045.
   PubMed Web of Science ®Google Scholar
• DUHL DM, RENHOWE PA: Inhibitors of kinesin motor proteins-research and clinical progress. Curr. Opin. Drug Discov. Devel. (2005) 8(4):431-436.
   PubMed Web of Science ®Google Scholar
• FERHAT L, COOK C, CHAUVIERE M et al.: Expression of the mitotic motor protein Eg5 in postmitotic neurons: implications for neuronal development. J. Neurosci. (1998) 18(19):7822-7835.
   PubMed Web of Science ®Google Scholar
• MARCUS AI, PETERS U, THOMAS SL et al.: Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J. Biol. Chem. (2005) 280(12):11569-11577.
   PubMed Web of Science ®Google Scholar
• MIGLARESE MR, WALLACE E, WOESSNER R et al.: ARRY-649, a member of a novel class of Eg5 kinesin inhibitors. J. Clin. Oncol. (2006) 24(18S):13045 (Abstract).
   Google Scholar
• MALIGA Z, KAPOOR TM, MITCHISON TJ: Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem. Biol. (2002) 9(9):989-996.
   PubMed Web of Science ®Google Scholar
• YAN Y, SARDANA V, XU B et al.: Inhibition of a mitotic motor protein: where, how, and conformational consequences. J. Mol. Biol. (2004) 335(2):547-554.
   PubMed Web of Science ®Google Scholar
• DEBONIS S, SIMORRE JP, CREVEL I et al.: Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry (2003) 42(2):338-349.
   PubMed Web of Science ®Google Scholar
• WALLACE E, WOESSNER R, ALLEN S et al.: ARRY-649: A potent and efficacious KSP inhibitor. 4th International Symposium on Targeted Anti-Cancer Therapies, Amsterdam, The Netherlands (2006):19 (Abstract).
   Google Scholar
• KAPOOR TM, MAYER TU, COUGHLIN ML, MITCHISON TJ: Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J. Cell Biol. (2000) 150(5):975-988.
   PubMed Web of Science ®Google Scholar
• MULLER C, GROSS D, SARLI V et al.: Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer Chemother. Pharmacol. (2006) (In Press).
   PubMedGoogle Scholar
• MARCUS AI, PETERS U, THOMAS SL et al.: Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J. Biol. Chem. (2005) 280(12):11569-11577.
   PubMed Web of Science ®Google Scholar
• WEIL D, GARCON L, HARPER M et al.: Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques (2002) 33(6):1244-1248.
   PubMed Web of Science ®Google Scholar
• McCABE FL, CAULDER E, INLOW-PORTER L et al.: SB-715992, a potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proceedings of the American Association for Cancer Research (2002) 43:1335 (Abstract).
   Google Scholar
• BOEHME M, BIENEK A, PIAZZA G et al.: Breadth of anti-tumor activity of CK0238273 (SB-715992), a novel inhibitor of the mitotic kinesin KSP. Proceedings of the American Association for Cancer Research (2002) 43:1337 (Abstract).
   Google Scholar
• ZHANG SY, GILMARTIN A, WOOD K, JACKSON K, HUANG P: Mitotic arrest in tumors as a pharmacodynamic marker for inhibition of the mitotic kinesin KSP by ispinesib, a novel KSP inhibitor. Clin. Cancer Res. (2005) 11(Suppl. 23):C196 (Abstract).
   Google Scholar
• ZHANG S, DIAMOND M, GIARDINIERE M et al.: Relationship between the antitumor activity of ispinesib, a novel KSP inhibitor, and neutropenia in a human xenograft model. Clin. Cancer Res. (2005) 11(Suppl. 23):C203 (Abstract).
   Google Scholar
• HEATH EI, ALOUSI A, EDER JP et al.: A Phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts) (2006) 25(Suppl. 18):2026 (Abstract).
   Google Scholar
• JONES SF, PLUMMER ER, BURRIS HA et al.: Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts) (2006) 25(Suppl. 18):2027 (Abstract).
   Web of Science ®Google Scholar
• CHU Q, TILL E, ROWINSKY EK et al.: Phase I study of ispinesib (SB-715992) in combination with capecitabine in patients with advanced solid tumors. Clin. Cancer Res. (2005) 11(Suppl. 23):C85 (Abstract).
   Google Scholar
• SEEBARAN A, MOLIFE R, PAYNE M et al.: Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors. Clin. Cancer Res. (2005) 11(Suppl. 23):C80 (Abstract).
   Google Scholar
• EL-KHOUEIRY AB, IQBAL S, SINGH DA et al.: A randomized Phase II non-comparative study of Ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P). J. Clin. Oncol. (Meeting Abstracts) (2006) 25(Suppl. 18):3595 (Abstract).
   Google Scholar
• MILLERK, NG C, ANG P et al.: Phase II, open label study of ispinesib in patients with localy advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium (2005):1089 (Abstract).
   Google Scholar
• HOLEN KD, BELANI CP, WILDING G et al.: Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. J. Clin. Oncol. (Meeting Abstracts) (2006) 25(Suppl. 18):2000 (Abstract).
   Web of Science ®Google Scholar
• STEIN MN, RUBIN EH, SCOTT PD et al.: Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):2001.
   Google Scholar
• KEEN N, TAYLOR S: Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer (2004) 4(12):927-936.
   PubMed Web of Science ®Google Scholar
• MATTHEWS N, VISINTIN C, HARTZOULAKIS B, JARVIS A, SELWOOD DL: Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev. Anti-Cancer Ther. (2006) 6(1):109-120.
   PubMed Web of Science ®Google Scholar
• HARRINGTON EA, BEBBINGTON D, MOORE J et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. (2004) 10(3):262-267.
   PubMed Web of Science ®Google Scholar
• RUBIN EH, SHAPIRO GI, STEIN MN et al.: A Phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):3009 (Abstract).
   Google Scholar
• WILKINSON RW, KEEN N, ODEDRA R et al.: AZD1152: a highly potent and specific aurora kinase inhibitor. Proc. Am. Assoc. Cancer Res. (2006) 47:5673 (Abstract).
   Google Scholar
• WALSH V, PEPPER C, MILLS C, BURNETT AK: The Aurora kinase inhibitor AZD1152 causes perturbation of cell cycle distribution in cell lines and primary AML samples. Blood (2005) 106(11):2759 (Abstract).
   Google Scholar
• OKE A, FOOT N, KEEN N et al.: The activity of the novel Aurora kinase B inhibitor AZD1152 in acute myeloid leukaemia cells. Blood (2005) 106(11):3374 (Abstract).
   PubMed Web of Science ®Google Scholar
• ODEDRA R, HEATON SP, KEEN N et al.: AZD-1152, highly potent aurora kinase inhibitor, with selectivity. Clin. Cancer Res. (2005) 11(Suppl. 23):B214 (Abstract).
   Google Scholar
• SCHELLENS JH, BOSS D, WITTEVEEN PO et al.: Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):3008 (Abstract).
   Google Scholar
• MANFREDI M, ECSEDY J, MEETZE K et al.: MLN8054, an orally active Aurora A kinase small molecule inhibitor in Phase I clinical trials. Proc. Am. Assoc. Cancer Res. (2006) 47:4724 (Abstract).
   Google Scholar
• ECSEDY JA, HOAR K, WYSONG DR et al.: Effect of Aurora A inhibition in cultured human tumor cells using a selective small molecule inhibitor MLN8054. Proc. Am. Assoc. Cancer Res. (2006) 47:2066 (Abstract).
   Google Scholar
• HUCK J, ZHANG M, BURENKOVA O et al.: Preclinical antitumor activity of MLN8054, a small molecule Aurora A kinase inhibitor. Proc. Amer. Assoc. Cancer Res. (2006) 47:4698 (Abstract).
   Google Scholar
• SMITH MR, WILSON ML, HAMANAKA R et al.: Malignant transformation of mammalian cells initiated by constitutive expression of the Polo-like kinase. Biochem Biophys. Res. Commun. (1997) 234(2):397-405.
   PubMed Web of Science ®Google Scholar
• STREBHARDT K, ULLRICH A: Targeting Polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer (2006) 6(4):321-330.
   PubMed Web of Science ®Google Scholar
• XIE S, XIE B, LEE MY, DAI W: Regulation of cell cycle checkpoints by Polo-like kinases. Oncogene (2005) 24(2):277-286.
   PubMed Web of Science ®Google Scholar
• ECKERDT F, YUAN J, STREBHARDT K: Polo-like kinases and oncogenesis. Oncogene (2005) 24(2):267-276.
   PubMed Web of Science ®Google Scholar
• TAKAI N, HAMANAKA R, YOSHIMATSU J, MIYAKAWA I: Polo-like kinases (Plks) and cancer. Oncogene (2005) 24(2):287-291.
   PubMed Web of Science ®Google Scholar
• STEEGMAIER M, BAUM A, SOLCA F et al.: BI 2536, a potent and highly selective inhibitor of Polo-like kinase 1 (Plk1), induces mitotic arrest and apoptosis in a broad spectrum of tumor cell lines. Clin. Cancer Res. (2005) 11(Suppl. 23):C192 (Abstract).
   Google Scholar
• BAUM A, GARIN-CHESA P, QUANT J et al.: In vivo activity of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in a range of human cancer xenograft models. Clin. Cancer Res. (2005) 11(Suppl. 23):C191 (Abstract).
   Google Scholar
• HOFHEINZ R, HOCHHAUS A, AL-BATRAN S et al.: A Phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):2038.
   PubMed Web of Science ®Google Scholar
• MUNZERT G, STEINBILD S, FROST A et al.: A Phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts) (2006) 24(Suppl. 18):3069 (Abstract).
   PubMed Web of Science ®Google Scholar